Payment overview · 2025
General Payments
$197.04
10 reported records · 6 companies
Healthcare provider profile · identity verified
Jeny Thomas, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LAKELAND, FL · NPI 1982166997
Verified facts
What the public records show
CMS Open Payments records show Jeny Thomas, NP received $197.04 in general payments during 2025 across 10 reported records.
GlaxoSmithKline, LLC. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.61 | 28.2% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $43.68 | 22.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.23 | 17.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.57 | 11.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.46 | 10.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.49 | 9.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $197.04 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $55.61 | 3 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $43.68 | 2 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 532 | 161 |
| Gabapentin | Gabapentin | 359 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 355 | 97 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 305 | 62 |
| Metformin Hcl | Metformin Hcl | 246 | 65 |
| Losartan Potassium | Losartan Potassium | 242 | 74 |
| Lisinopril | Lisinopril | 235 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 57 |
| Omeprazole | Omeprazole | 215 | 55 |
| Montelukast Sodium | Montelukast Sodium | 187 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 37 |
| Famotidine | Famotidine | 151 | 42 |
| Trazodone Hcl | Trazodone Hcl | 145 | 43 |
| Simvastatin | Simvastatin | 136 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 129 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 120 | 41 |
| Furosemide | Furosemide | 111 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 31 |
| Jardiance | Empagliflozin | 104 | 19 |
| Ibuprofen | Ibuprofen | 99 | 38 |
| Carvedilol | Carvedilol | 94 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 20 |
| Ezetimibe | Ezetimibe | 92 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 88 | 17 |
| Glipizide | Glipizide | 84 | 26 |
| Potassium Chloride | Potassium Chloride | 84 | 15 |
| Clonidine Hcl | Clonidine Hcl | 81 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 80 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 21 |
| Alendronate Sodium | Alendronate Sodium | 78 | 20 |
| Azithromycin | Azithromycin | 75 | 66 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 17 |
| Baclofen | Baclofen | 73 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 19 |
| Eliquis | Apixaban | 71 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 22 |
| Alprazolam | Alprazolam | 67 | 19 |
| Glipizide Er | Glipizide | 67 | 17 |
| Nifedipine Er | Nifedipine | 67 | 16 |
| Meclizine Hcl | Meclizine Hcl | 66 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 19 |
| Fenofibrate | Fenofibrate | 62 | 15 |
| Sucralfate | Sucralfate | 61 | 15 |
| Buspirone Hcl | Buspirone Hcl | 59 | 14 |
| Prednisone | Prednisone | 59 | 52 |
| Januvia | Sitagliptin Phosphate | 58 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | 18 |
| Tramadol Hcl | Tramadol Hcl | 56 | 26 |
| Trulicity | Dulaglutide | 56 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 24 |
| Sertraline Hcl | Sertraline Hcl | 54 | 18 |
| Glimepiride | Glimepiride | 52 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 51 | 17 |
| Clonazepam | Clonazepam | 50 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 11 |
| Allopurinol | Allopurinol | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 35 |
| Fenofibrate | Fenofibrate,micronized | 39 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 11 |
| Clotrimazole | Clotrimazole | 37 | suppressed |
| Meloxicam | Meloxicam | 36 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | 19 |
| Spironolactone | Spironolactone | 28 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | 11 |
| Risperidone | Risperidone | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 17 |
| Atenolol | Atenolol | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | 11 |
| Lactulose | Lactulose | 20 | 13 |
| Telmisartan | Telmisartan | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Constulose | Lactulose | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | 13 |
| Tolterodine Tartrate | Tolterodine Tartrate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | 14 |
| Tradjenta | Linagliptin | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $197.04 · 10 records | GlaxoSmithKline, LLC. | AIRSUPRA, BENLYSTA, Bimzelx, CAPVAXIVE, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, RINVOQ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error